Genmab A/S shares have seen multiple activities recently, from being acquired by various entities such as
Allspring Global Investments Holdings LLC,
Capstone Investment Advisors LLC and
GAMMA Investing LLC, to being sold by others like
Goldman Sachs Group Inc and
Sequoia Financial Advisors LLC. The
share buy-back program was completed, and its resumption and advancement have also been reported. Despite a slip in share prices, Genmab's 'Evolution' continues with a $1.8 billion deal to acquire cancer drug developer,
ProfoundBio. Additionally, the firm's Q1 2024 earnings have been affirmed by
HC Wainwright and the price target was raised to $47.00 by
BTIG Research. Genmab's reported Q1 revenue showed a whopping 46% rise compared to the previous year, and DARZALEX's robust sales further favor the firm. However, early data from a
lung cancer study caused a dip in shares. Meanwhile, the institutional owners of Genmab may consider drastic measures due to recent long-term losses.
Genmab Stocks News Analytics from Wed, 02 Nov 2016 07:00:00 GMT to Sun, 14 Jul 2024 17:41:08 GMT -
Rating 0
- Innovation -2
- Information 6
- Rumor -4
